Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of pseudomonas aeruginosa–induced pneumonia

REFERENCES

• Pfeifer Y, Cullik A, Witte W: Resistance to cephalosporins and carbapenems in gram-negative bacterial pathogens. Int J Med Microbiol. 2010;300:371–379.
   PubMed Web of Science ®Google Scholar
• Veesenmeyer JL, Hauser AR, Lisboa T, Rello J: Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med. 2009;37:1777–1786.
   PubMed Web of Science ®Google Scholar
• Page MG, Heim J: Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol. 2009;9:558–565.
   PubMed Web of Science ®Google Scholar
• Bhavsar T, Liu M, Hardej D, Liu X, Cantor J: Aerosolized recombinant human lysozyme ameliorates Pseudomonas aeruginosa-induced pneumonia in hamsters. Exp Lung Res. 2010;36:94–100.
   PubMed Web of Science ®Google Scholar
• Gavrilenko TI, Siurin SA, Lolaeva LT, Savchenko VM: The characteristics of lysozyme and carbenicillin action on the clinico-immunological status of patients with chronic bronchitis. Lik Sprava. 1992;8:42–45.
   PubMedGoogle Scholar
• Bukharin OV, Zykova LS, Tarasenko NF: Experimental and clinical study of the use of lysozyme in combination with chemotherapeutic agents. Antibiot Med Biotekhnol. 1986;31:917–920.
   PubMedGoogle Scholar
• Luniakin AA, Bogomaz TA: Lysozyme in the overall treatment of children with an influenza infection and pneumonia. Pediatr Akus Ginekol. 1977;1:11–13.
   PubMedGoogle Scholar
• Bonapace CR, Friedrich LV, Bosso JA, White RL: Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. Antimicrob Agents Chemother. 2002;11:3574–3579.
   Google Scholar
• Omri A, Suntres ZE, Shek PN: Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol. 2002;64:1407–1413.
   PubMed Web of Science ®Google Scholar
• Szarka RJ, Wang N, Gordon L, Nation PN, Smith RH: A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. J Immunol Methods. 1997;202:49–57.
   PubMed Web of Science ®Google Scholar
• Escudero C, Quirce S, Fernandez-Nieto M, Miguel J, Cuesta J, Sastre J: Egg white proteins as inhalant allergens associated with baker's asthma. Allergy. 2003;58:616–620.
   PubMed Web of Science ®Google Scholar
• Park HS, Nahm DH: New occupational allergen in a pharmaceutical industry: serratial peptidase and lysozyme chloride. Ann Allergy Asthma Immunol. 1997;78:225–229.
   PubMed Web of Science ®Google Scholar
• Holen E, Elsayed S: Characterization of four major allergens of hen egg-white by IEF/SDS-PAGE combined with electrophoretic transfer and IgE-immunoautoradiography. Int Arch Allergy Appl Immunol. 1990;91:136–141.
   PubMedGoogle Scholar
• Cole AM, Liao HI, Stuchlik O, Tilan J, Pohl J, Ganz T: Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol. 2002;169:6985–6991.
   PubMed Web of Science ®Google Scholar
• Loeffler J, Djurkovic S, Fischetti VA: Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun. 2003;71:6199–6204.
   PubMed Web of Science ®Google Scholar
• Cole AM, Thapa DR, Gabayan V, Liao HI, Liu L, Ganz T: Decreased clearance of Pseudomonas aeruginosa from airways of mice deficient in lysozyme M. J Leuk Biol. 2005;78:1081–1085.
   PubMed Web of Science ®Google Scholar
• Markart P, Korfhagen TR, Weaver TE, Akinbi HT: Mouse lysozyme M is important in pulmonary host defense against Klebsiella pneumoniae infection. Am J Respir Crit Care Med. 2004;169:454–458.
   Google Scholar
• Akinbi HT, Epaud R, Bhatt H, Weaver TE: Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J Immunol. 2000;165:5760–5766.
   PubMed Web of Science ®Google Scholar
• Neu HC, Dreyfus J 3rd, Canfield RE: Effect of human lysozyme on gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 1968;8:442–444.
   PubMedGoogle Scholar
• Travis SM, Singh PK, Welsh MJ: Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol. 2001;13:89–95.
   PubMed Web of Science ®Google Scholar
• Singh PK, Tack BF, McCray PB Jr, Welsh MJ: Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol. 2000;279:L799–L805.
   PubMed Web of Science ®Google Scholar
• Scott MG, Hancock RE: Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol. 2000;20:407–431.
   PubMed Web of Science ®Google Scholar
• Travis SM, Conway BA, Zabner J, Smith JJ, Anderson NN, Singh PK, Greenberg EP, Welsh MJ: Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol. 1999;20:872–879.
   PubMed Web of Science ®Google Scholar
• Ellison RT III, Giehl TJ: Killing of Gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest. 1991;88:1080–1091.
   PubMed Web of Science ®Google Scholar
• Nash JA, Ballard TN, Weaver TE, Akinbi HT: The peptidoglycan-degrading property of lysozyme is not required for bactericidal activity in vivo. J Immunol. 2006;177;519–526.
   PubMed Web of Science ®Google Scholar
• Ibrahim HR, Thomas U, Pellegrini A: A helix-loop-helix peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. J Biol Chem. 2001;276:43767–43774.
   PubMed Web of Science ®Google Scholar
• Kuhn RJ: Formulation of aerosolized therapeutics. Chest. 2001;120:94S–98S.
   PubMed Web of Science ®Google Scholar